Introduction {#S1}
============

The Ewing sarcoma family of tumors (ESFT) comprises a group of small, round, blue cell neoplasms that primarily affect the skeleton in adolescent children. The incidence is approximately 2.8 per million in the United States and has remained relatively stable over the past few decades ([@B1]). ESFT often amalgamates both Ewing sarcoma and primitive neuroectodermal tumors (PNETs), owing to similar histology, treatment, and outcome ([@B2]). PNETs are overall uncommon neoplasms that are thought to have a similar stem cell of origin as Ewing sarcoma, and thus, the treatment and outcomes of both are thought to be correlated ([@B2]). Both are also unified by the presence of the EWS--ETS fusion protein. However, although both Ewing sarcoma and PNET arise from neuroectoderm, PNET histopathologically display more developed cytological features of neural cells. Poor prognostic factors for ESFT include axial location, larger tumor size/volume, presence of metastatic disease, male gender, and older age ([@B3]--[@B8]).

The Ewing sarcoma family of tumors uncommonly occurs in adults, although the line that distinguishes the ages of adolescent children and adults is often blurred. Studies often define "adult" patients as 16 years or older, which may be inconsistent with other studies and/or provide a misrepresentation of the patient population ([@B9]). Currently, there are no studies using population-based databases that examine differential clinical factors between pediatric and adult cohorts. It is unlikely that prospective studies, or even comparatively large retrospective cohorts, would be able to accumulate large volumes of patients of adult ESFTs to permit robust conclusions.

Therefore, analyses of large population-based databases such as the Surveillance, Epidemiology, and End Results (SEER) database are valuable for these uncommon cases. The objective of this study was to compare clinical characteristics of pediatric (≤18 years) vs. adult (\>18 years) ESFTs, impact of surgery and radiation therapy (RT) on both groups, and factors associated with overall survival (OS).

Materials and Methods {#S2}
=====================

To analyze large volumes of patients with ESFT, we utilized the SEER registry, which encompasses an estimated 28% of the US population, including minority populations ([@B10]). The patient population was assembled using the histology codes 9260, 9364, or 9365. A total of 1,870 patients from 1983 to 2013 were selected for analysis, 976 of which were pediatric cases (≤18 years) and 894 adult cases (\>18 years). All the cases with missing data were included in efforts to avoid biases.

Between the two groups, demographic, tumor, and treatment characteristics were then collated and compared. Receipt of RT was coded as external-beam, radioactive implants, or radioisotopes; cancer-directed surgery referred to local tumor excision, amputation, or surgical therapy not otherwise specified. Both were similar to existing SEER publications in this tumor type ([@B11], [@B12]). All statistical calculations were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA), and *p* \< 0.05 was considered statistically significant. The chi-square test was used to compare the differences in proportions for the baseline clinical characteristics between groups. Survival analysis was carried out using the Kaplan--Meier method, and distributions were compared using the log-rank test. For OS, events were defined as death from any cause. For cancer-specific survival (CSS), events were defined as death from cancer. Deaths from all other reasons and those alive at the time of analysis were censored. Univariate analysis was performed to identify factors associated with the primary endpoint, OS. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using Cox proportional hazards regression. To adjust for potential confounding variables, multivariate analysis was done. Only the variables positively associated with OS in the univariate analysis were elected for multivariable adjusted models (*p* ≤ 0.05 as a cutoff).

Results {#S3}
=======

In the entire cohort (*n* = 1,870), median survival was 103 months (95% CI 78--145); 5- and 10-year OS were 55 and 49%, respectively. Median CSS was 143 months (95% CI 99--258); 5- and 10-year CSS were 57 and 51%, respectively.

Table [1](#T1){ref-type="table"} displays clinical parameters of both pediatric (*n* = 976) and adult (*n* = 894) populations. In short, adult patients were more likely to present with distant metastasis (DM), soft tissue primary site, and PNET histology.

###### 

**Clinical characteristics of the entire population as well as pediatric and adult subsets**.

                                        Total, *N*   Pediatric, *N* (%)   Adult, *N* (%)   *p* Value
  ------------------------------------- ------------ -------------------- ---------------- --------------------------------------------
  Total number                          1,870        976                  894              
  Age                                                                                      **\<0.001[a](#tfn1){ref-type="table-fn"}**
   Median (range)                       18 (0--89)   13 (0--18)           29 (19--89)      
  Gender                                                                                   0.936
   Male                                 1,111        579 (59)             532 (60)         
   Female                               759          397 (41)             362 (40)         
  Race                                                                                     0.202
   White                                1,638        864 (89)             774 (87)         
   Non-white                            232          112 (11)             120 (13)         
  Marital status                                                                           **\<0.001**
   Yes                                  359          3 (0)                356 (40)         
   No                                   1,511        973 (100)            538 (60)         
  SEER stage                                                                               **\<0.001**
   Locoregional                         1,170        662 (68)             508 (57)         
   Distant                              545          255 (26)             290 (33)         
   Missing                              155          56 (6)               87 (10)          
  Size                                                                                     0.156
   \<8 cm                               495          256 (52)             239 (56)         
   ≥8 cm                                599          284 (14)             315 (16)         
   Missing                              776          436 (33)             340 (28)         
  Primary site                                                                             **\<0.001**
   Extremities (bones)                  556          367 (38)             189 (21)         
   Axial bones                          715          407 (42)             308 (35)         
   Soft tissue                          415          164 (17)             251 (28)         
   Other                                170          35 (4)               135 (15)         
   Missing                              14           3 (0)                11 (1)           
  Lymph node                                                                               0.163
   Yes                                  94           42 (4)               52 (6)           
   No                                   1,052        549 (57)             503 (56)         
   Missing                              724          385 (39)             339 (38)         
  Histology                                                                                **\<0.001**
   Ewing sarcoma                        1,565        873 (89)             692 (77)         
   PNET                                 305          103 (11)             202 (23)         
  Grade                                                                                    0.600
   Low                                  18           8 (1)                10 (1)           
   High                                 449          169 (17)             280 (31)         
   Missing                              1,403        799 (82)             604 (68)         
  Year of diagnosis                                                                        **\<0.001**
   1983--1993                           411          261 (27)             150 (17)         
   1994--2003                           648          309 (32)             339 (38)         
   2004--2013                           811          406 (41)             405 (45)         
  Radiotherapy                                                                             0.054
   Yes                                  893          490 (50)             403 (45)         
   No                                   933          470 (48)             463 (52)         
   Missing                              44           16 (2)               28 (3)           
  Cancer surgery                                                                           0.054
   Yes                                  1,040        558 (57)             482 (54)         
   No                                   675          330 (34)             345 (39)         
   Missing                              155          86 (9)               58 (7)           
  Radiation/surgery sequence                                                               0.894
   Radiation before surgery             81           40 (4)               41 (5)           
   Radiation after surgery              380          196 (20)             184 (21)         
   Radiation before and after surgery   10           6 (1)                4 (0)            
   No radiation or no surgery           1,396        733 (75)             663 (74)         
   Missing                              3            1 (0)                2 (0)            
  Living status                                                                            **\<0.001**
   Alive                                995          617 (63)             378 (42)         
   Dead                                 875          359 (37)             516 (58)         
  Cancer-specific survival                                                                 **\<0.001**
   Alive                                995          617 (64)             378 (42)         
   Cancer-specific death                784          324 (33)             460 (52)         
   Other death                          53           19 (2)               34 (4)           
   Unknown death                        38           9 (1)                17 (2)           

*^a^Wilcoxon rank-sum test utilization instead of chi-square test. Missing data were not included for p value calculations*.

*SEER, surveillance, epidemiology, and end results; PNET, primitive neuroectodermal tumor*.

*Bold means statistically significant (p \< 0.05)*.

Adult patients with ESFT had a worse prognosis (5-year OS of 43% for adult vs. 66% for pediatrics, log-rank *p* \< 0.001) (Figure [1](#F1){ref-type="fig"}). In both patient cohorts, surgery was associated with a large magnitude of OS improvement (Figure [2](#F2){ref-type="fig"}). When stratified by receipt of surgery, adults had worse 5-year OS, both with (56 vs. 73%, log-rank *p* \< 0.001) and without surgery (25 vs. 57%, log-rank *p* \< 0.001) (Figure [2](#F2){ref-type="fig"}). In patients without surgery, RT was associated with improved OS (Figure [3](#F3){ref-type="fig"}). However, in patients who had surgery, RT failed to improve OS (Figure [3](#F3){ref-type="fig"}).

![**Overall survival in pediatric (blue line) vs. adult (red line) patients**.](fonc-07-00082-g001){#F1}

![**Overall survival in pediatric and adult patients as stratified by receipt of surgery**. Red line denotes pediatric patients undergoing surgery; brown line pediatric patients without surgery; blue line adult patients undergoing surgery; green line adult patients without surgery.](fonc-07-00082-g002){#F2}

![**Overall survival in pediatric and adult patients with and without surgery as stratified by receipt of radiotherapy**. Green line denotes surgery alone; blue line surgery and radiotherapy; red line radiotherapy alone; brown line neither surgery nor radiotherapy.](fonc-07-00082-g003){#F3}

Table [2](#T2){ref-type="table"} displays univariate and multivariate analyses of factors associated with OS in the whole cohort. Adulthood conferred an independent association with worse OS on multivariate analysis. Other salient factors associated with OS were male gender, metastatic disease, non-extremity bone location, and PNET histology. Of note, receipt of RT was not correlated in itself or with respect to surgery. In addition, OS was increased with diagnosis/treatment in recent years compared to the past, likely owing to better techniques and therapies. When examining pediatric (Table [3](#T3){ref-type="table"}) and adult (Table [4](#T4){ref-type="table"}) patients separately with multivariate analysis of factors associated with OS, similar parameters were identified in both groups. Notably, gender was a factor in adult but not pediatric patients.

###### 

**Univariate and multivariate analyses of factors associated with overall survival**.

  Parameter                                             *N*         Univariate             Multivariate                          
  ----------------------------------------------------- ----------- ---------------------- -------------- ---------------------- -------------
  Age \>18 vs. ≤18                                      894/976     2.062 (1.800--2.363)   **\<0.001**    1.869 (1.622--2.154)   **\<0.001**
  Gender: male vs. female                               1,111/759   1.207 (1.051--1.385)   **0.008**      1.211 (1.054--1.392)   **0.007**
  Race: non-white vs. white                             232/1,638   1.179 (0.966--1.439)   0.105                                 
  Stage: metastatic vs. non-metastatic                  545/1,170   3.181 (2.763--3.663)   **\<0.001**    2.671 (2.301--3.100)   **\<0.001**
  Primary tumor site: axial bones vs. extremity bones   715/556     1.515 (1.279--1.795)   **\<0.001**    1.227 (1.032--1.460)   **0.021**
  Primary tumor site: soft tissue vs. extremity bones   415/556     1.460 (1.200--1.778)   **\<0.001**    1.301 (1.041--1.625)   **0.021**
  Primary tumor site: other vs. extremity bones         170/556     2.202 (1.730--2.802)   **\<0.001**    1.500 (1.134--1.985)   **0.005**
  Histology: PNET vs. Ewing                             305/1,565   1.521 (1.287--1.796)   **\<0.001**    1.302 (1.064--1.593)   **0.011**
  Year of diagnosis: 1993--2002 vs. 1983--1992          648/411     0.986 (0.836--1.163)   0.867          0.805 (0.673--0.964)   **0.019**
  Year of diagnosis: 2003--2013 vs. 1983--1992          811/411     0.799 (0.670--0.954)   **0.013**      0.703 (0.582--0.849)   **\<0.001**
  Radiotherapy: yes vs. no                              893/933     1.058 (0.925--1.212)   0.411          0.922 (0.801--1.060)   0.252
  Cancer surgery: yes vs. no                            1,040/675   0.477 (0.414--0.549)   **\<0.001**    0.591 (0.509--0.687)   **\<0.001**
  Radiotherapy after surgery vs. prior to surgery       380/81      1.026 (0.712--1.477)   0.892                                 

*HR, hazard ratio; CI, confidence interval; PNET, primitive neuroectodermal tumor*.

*Bold means statistically significant (p \< 0.05)*.

###### 

**Univariate and multivariate analyses of factors associated with overall survival in pediatric patients**.

  Parameter                                             *N*       Univariate             Multivariate                          
  ----------------------------------------------------- --------- ---------------------- -------------- ---------------------- -------------
  Gender: male vs. female                               579/397   1.159 (0.935--1.437)   0.178                                 
  Race: non-white vs. white                             112/864   0.972 (0.634--1.490)   0.896                                 
  Stage: metastatic vs. non-metastatic                  255/662   3.668 (2.864--4.697)   **\<0.001**    2.763 (2.384--3.201)   **\<0.001**
  Primary tumor site: axial bones vs. extremity bones   407/367   1.696 (1.303--2.208)   **\<0.001**    1.281 (1.081--1.518)   **0.004**
  Primary tumor site: soft tissue vs. extremity bones   164/367   1.221 (0.817--1.826)   0.330          1.593 (1.303--1.947)   **\<0.001**
  Primary tumor site: other vs. extremity bones         35/367    1.820 (0.742--4.467)   0.191          2.107 (1.649--2.692)   **\<0.001**
  Histology: PNET vs. Ewing                             103/873   1.235 (0.708--2.152)   0.457                                 
  Year of diagnosis: 1994--2003 vs. 1983--1993          309/261   0.645 (0.475--0.877)   **0.005**      0.913 (0.771--1.081)   0.292
  Year of diagnosis: 2004--2013 vs. 1983--1993          405/261   0.439 (0.294--0.656)   **\<0.001**    0.768 (0.641--0.920)   **0.004**
  Radiotherapy: yes vs. no                              490/470   1.460 (1.174--1.816)   **0.001**      0.882 (0.769--1.012)   0.073
  Cancer surgery: yes vs. no                            558/330   0.533 (0.423--0.671)   **\<0.001**    0.584 (0.507--0.672)   **\<0.001**
  Radiotherapy after surgery vs. prior to surgery       196/40    0.710 (0.426--1.186)   0.191                                 

*HR, hazard ratio; CI, confidence interval; PNET, primitive neuroectodermal tumor*.

*Bold means statistically significant (p \< 0.05)*.

###### 

**Univariate and multivariate analyses of factors associated with overall survival in adult patients**.

  Parameter                                             *N*       Univariate             Multivariate                          
  ----------------------------------------------------- --------- ---------------------- -------------- ---------------------- -------------
  Gender: male vs. female                               532/362   1.259 (1.052--1.507)   **0.012**      1.213 (1.056--1.393)   **0.006**
  Race: non-white vs. white                             120/774   1.189 (0.923--1.531)   0.181                                 
  Marital status: yes vs. no                            356/538   1.160 (0.973--1.382)   0.098                                 
  Stage: metastatic vs. non-metastatic                  290/508   2.960 (2.454--3.570)   **\<0.001**    2.749 (2.371--3.187)   **\<0.001**
  Primary tumor site: axial bones vs. extremity bones   308/189   1.334 (1.041--1.710)   **0.023**      1.253 (1.058--1.484)   **0.009**
  Primary tumor site: soft tissue vs. extremity bones   251/189   1.325 (1.021--1.719)   **0.034**      1.379 (1.111--1.711)   **0.004**
  Primary tumor site: other vs. extremity bones         135/189   1.773 (1.324--2.374)   **0.001**      1.811 (1.386--2.366)   **\<0.001**
  Histology: PNET vs. Ewing                             202/692   1.618 (1.332--1.964)   **\<0.001**    1.315 (1.079--1.603)   **0.007**
  Year of diagnosis: 1994--2003 vs. 1983--1993          339/150   1.207 (0.913--1.596)   0.187                                 
  Year of diagnosis: 2004--2013 vs. 1983--1993          405/150   1.098 (0.788--1.531)   0.581                                 
  Radiotherapy: yes vs. no                              403/463   0.828 (0.694--0.989)   **0.037**      0.882 (0.769--1.012)   0.073
  Cancer surgery: yes vs. no                            482/345   0.427 (0.356--0.513)   **\<0.001**    0.591 (0.510--0.686)   **\<0.001**
  Radiotherapy after surgery vs. prior to surgery       184/41    1.446 (0.858--2.437)   0.166                                 

*HR, hazard ratio; CI, confidence interval; PNET, primitive neuroectodermal tumor*.

*Bold means statistically significant (p \< 0.05)*.

Because testing for the EWS/FLI translocation became available in the mid to late 1990s, we sought to further investigate the subset treated in the most recent decade (2004--2013), during which the most modern paradigms of diagnosis and treatment were most likely to be utilized. Table [5](#T5){ref-type="table"} (analogous to Table [1](#T1){ref-type="table"}) displays similar comparisons between pediatric and adult groups, although notably, receipt of RT was no longer statistically significant. When comparing survival in this cohort, there were similar conclusions (e.g., adults had poorer prognosis and surgery improved survival), with one exception. In the overall cohort of patients (Figure [4](#F4){ref-type="fig"}), RT did not improve OS in adults and was associated with worse OS in pediatrics; the same was not true in the most modern subset (Figure [5](#F5){ref-type="fig"}). There was no statistical difference in OS with or without RT in pediatric patients; moreover, adults receiving RT had such with a significant improvement in OS. Tables [6](#T6){ref-type="table"}--[8](#T8){ref-type="table"} (analogous to Tables [2](#T2){ref-type="table"}--[4](#T4){ref-type="table"}) illustrate that RT was independently associated with OS in all patients as well as adult and pediatric subsets separately. Of note, this difference was observed only on multivariate analysis (non-significant on univariate analysis), potentially relating to interaction with factors that were significant on univariate but non-significant on multivariate analysis (e.g., some comparisons of primary site).

###### 

**Clinical characteristics of the entire population from 2004 to 2013 as well as pediatric and adult subsets**.

                                        Total, *N*   Pediatric, *N* (%)   Adult, *N* (%)   *p* Value
  ------------------------------------- ------------ -------------------- ---------------- --------------------------------------------
  Total number                          811          406                  405              
  Age                                                                                      **\<0.001[a](#tfn2){ref-type="table-fn"}**
   Median (range)                       18 (0--89)   13 (0--18)           29 (19--89)      
  Gender                                                                                   0.700
   Male                                 474          240 (59)             234 (58)         
   Female                               337          166 (41)             171 (42)         
  Race                                                                                     0.684
   White                                689          347 (85)             342 (84)         
   Non-white                            122          59 (15)              63 (16)          
  Marital status                                                                           **\<0.001**
   Yes                                  146          2 (0.5)              144 (36)         
   No                                   665          404 (99.5)           261 (64)         
  SEER stage                                                                               **0.007**
   Locoregional                         511          279 (69)             232 (57)         
   Distant                              241          106 (26)             135 (33)         
   Missing                              59           21 (5)               38 (10)          
  Size                                                                                     **0.045**
   \<8 cm                               250          134 (33)             116 (29)         
   ≥8 cm                                318          144 (35)             174 (43)         
   Missing                              243          128 (32)             215 (28)         
  Primary site                                                                             **\<0.001**
   Extremities (bones)                  212          132 (33)             80 (20)          
   Axial bones                          293          162 (40)             131 (32)         
   Soft tissue                          213          91 (22)              122 (30)         
   Other                                87           20 (5)               67 (17)          
   Missing                              6            1 (0.3)              5 (1)            
  Lymph node                                                                               **0.637**
   Yes                                  61           30 (7)               31 (8)           
   No                                   642          336 (83)             306 (75)         
   Missing                              108          40 (10)              68 (17)          
  Histology                                                                                **\<0.001**
   Ewing sarcoma                        676          361 (89)             315 (78)         
   PNET                                 135          45 (11)              90 (22)          
  Grade                                                                                    **0.622**
   Low                                  9            4 (1)                5 (1)            
   High                                 168          61 (15)              107 (27)         
   Missing                              634          341 (84)             293 (72)         
  Year of diagnosis                                                                        0.113
   2004--2008                           387          205 (50)             182 (45)         
   2009--2013                           424          201 (50)             223 (55)         
  Radiotherapy                                                                             0.560
   Yes                                  371          191 (47)             180 (44)         
   No                                   431          213 (52.5)           218 (54)         
   Missing                              9            2 (0.5)              7 (2)            
  Cancer surgery                                                                           **0.014**
   Yes                                  489          265 (65)             224 (55)         
   No                                   301          136 (34)             165 (41)         
   Missing                              21           5 (1)                16 (4)           
  Radiation/surgery sequence                                                               0.169
   Radiation before surgery             28           9 (2)                19 (4.7)         
   Radiation after surgery              179          94 (23)              85 (21)          
   Radiation before and after surgery   1            0 (0)                1 (0.25)         
   No radiation or no surgery           602          303 (75)             299 (73.8)       
   Missing                              1            0 (0)                1 (0.25)         
  Living status                                                                            **\<0.001**
   Alive                                536          318 (78)             218 (54)         
   Dead                                 275          88 (22)              187 (46)         
  Cancer-specific survival                                                                 **\<0.001**
   Alive                                536          318 (78.3)           218 (54)         
   Cancer-specific death                255          83 (20.4)            172 (42)         
   Other death                          11           4 (1)                7 (2)            
   Unknown death                        9            1 (0.3)              8 (2)            

*^a^Wilcoxon rank-sum test utilization instead of chi-square test. Missing data were not included in p value calculations*.

*SEER, surveillance, epidemiology, and end results; PNET, primitive neuroectodermal tumor*.

*Bold means statistically significant (p \< 0.05)*.

![**Overall survival in pediatric and adult patients without surgery as stratified by receipt of radiotherapy**. Brown line denotes pediatric patients without radiotherapy; red line pediatric patients undergoing radiotherapy; blue line adult patients undergoing radiotherapy; green line adult patients without radiotherapy.](fonc-07-00082-g004){#F4}

![**In the 2004--2013 cohort, overall survival in pediatric and adult patients as stratified by receipt of radiotherapy**. Brown line denotes pediatric patients without radiotherapy; red line pediatric patients undergoing radiotherapy; blue line adult patients undergoing radiotherapy; green line adult patients without radiotherapy.](fonc-07-00082-g005){#F5}

###### 

**Of the 2004--2013 cohort, univariate and multivariate analyses of factors associated with overall survival**.

  Parameter                                             *N*       Univariate             Multivariate                          
  ----------------------------------------------------- --------- ---------------------- -------------- ---------------------- -------------
  Age \>18 vs. ≤18                                      405/406   3.835 (2.565--5.732)   **\<0.001**    2.367 (1.812--3.093)   **\<0.001**
  Gender: male vs. female                               474/337   1.109 (0.869--1.415)   0.405                                 
  Race: non-white vs. white                             122/689   1.423 (1.043--1.940)   **0.026**                             
  Stage: metastatic vs. non-metastatic                  241/511   3.328 (2.185--5.067)   **\<0.001**    4.056 (3.071--5.358)   **\<0.001**
  Primary tumor site: axial bones vs. extremity bones   293/212   1.655 (1.176--2.327)   **0.004**      1.258 (0.884--1.788)   0.202
  Primary tumor site: soft tissue vs. extremity bones   213/212   1.729 (1.203--2.485)   **0.003**      1.417 (0.958--2.098)   0.081
  Primary tumor site: other vs. extremity bones         87/212    2.566 (1.684--3.908)   **\<0.001**    1.422 (0.906--2.231)   0.126
  Histology: PNET vs. Ewing                             135/676   1.786 (1.352--2.358)   **\<0.001**    1.443 (1.058--1.968)   **0.021**
  Radiotherapy: yes vs. no                              371/431   0.960 (0.756--1.219)   0.739          0.776 (0.604--0.998)   **0.048**
  Cancer surgery: yes vs. no                            489/301   0.351 (0.275--0.448)   **\<0.001**    0.519 (0.399--0.676)   **\<0.001**
  Radiotherapy after surgery vs. prior to surgery       179/28    1.150 (0.554--2.384)   0.708                                 

*HR, hazard ratio; CI, confidence interval; PNET, primitive neuroectodermal tumor*.

*Bold means statistically significant (p \< 0.05)*.

###### 

**Of the 2004--2013 cohort, univariate and multivariate analyses of factors associated with overall survival in pediatric patients**.

  Parameter                                             *N*       Univariate             Multivariate                          
  ----------------------------------------------------- --------- ---------------------- -------------- ---------------------- -------------
  Gender: male vs. female                               240/166   0.990 (0.495--1.981)   0.977                                 
  Race: non-white vs. white                             59/347    2.061 (0.897--4.733)   0.088                                 
  Stage: metastatic vs. non-metastatic                  106/279   7.932 (4.416--14.25)   **\<0.001**    4.066 (3.094--5.343)   **\<0.001**
  Primary tumor site: axial bones vs. extremity bones   162/132   2.172 (1.194--3.950)   **0.011**      1.234 (0.878--1.733)   0.226
  Primary tumor site: soft tissue vs. extremity bones   91/132    2.137 (0.952--4.798)   0.066          1.767 (1.236--2.525)   **0.002**
  Primary tumor site: other vs. extremity bones         20/132    5.715 (1.161--28.14)   **0.032**      2.200 (1.456--3.326)   **\<0.001**
  Histology: PNET vs. Ewing                             45/361    1.416 (0.553--3.629)   0.469                                 
  Radiotherapy: yes vs. no                              191/213   1.181 (0.589--2.368)   0.639          0.771 (0.601--0.989)   **0.040**
  Cancer surgery: yes vs. no                            265/136   0.409 (0.216--0.773)   **0.006**      0.474 (0.366--0.615)   **\<0.001**
  Radiotherapy after surgery vs. prior to surgery       94/9      1.298 (0.300--5.624)   0.727                                 

*HR, hazard ratio; CI, confidence interval; PNET, primitive neuroectodermal tumor*.

*Bold means statistically significant (p \< 0.05)*.

###### 

**Of the 2004--2013 cohort, univariate and multivariate analyses of factors associated with overall survival in adult patients**.

  Parameter                                             *N*       Univariate             Multivariate                          
  ----------------------------------------------------- --------- ---------------------- -------------- ---------------------- -------------
  Gender: male vs. female                               234/171   1.149 (0.855--1.544)   0.358                                 
  Race: non-white vs. white                             63/342    1.288 (0.875--1.897)   0.200                                 
  Stage: metastatic vs. non-metastatic                  135/232   3.915 (2.848--5.382)   **\<0.001**    4.108 (3.126--5.398)   **\<0.001**
  Primary tumor site: axial bones vs. extremity bones   131/80    1.422 (0.910--2.222)   0.123          1.214 (0.863--1.706)   0.265
  Primary tumor site: soft tissue vs. extremity bones   122/80    1.376 (0.874--2.167)   0.168          1.463 (0.996--2.151)   0.053
  Primary tumor site: other vs. extremity bones         67/80     1.686 (1.025--2.775)   **0.040**      1.874 (1.216--2.887)   **0.004**
  Histology: PNET vs. Ewing                             90/315    1.577 (1.145--2.171)   **0.005**      1.573 (1.151--2.151)   **0.005**
  Radiotherapy: yes vs. no                              180/218   0.709 (0.528--0.951)   **0.022**      0.763 (0.594--0.979)   **0.034**
  Cancer surgery: yes vs. no                            224/165   0.330 (0.243--0.446)   **\<0.001**    0.489 (0.377--0.634)   **\<0.001**
  Radiotherapy after surgery vs. prior to surgery       85/19     1.291 (0.544--3.062)   0.562                                 

*HR, hazard ratio; CI, confidence interval; PNET, primitive neuroectodermal tumor*.

*Bold means statistically significant (p \< 0.05)*.

Discussion {#S4}
==========

Despite some small studies that have claimed no differences between the behavior of ESFTs in children and adults ([@B2]), the use of a national database with large volumes determines that there are important differences. We determine clinical characteristics that are differentially associated with adult ESFT, describe which populations radiotherapy may benefit, and describe parameters associated with OS in ESFTs regardless of age.

Our results are similar to other data in that metastatic disease, treatment era, location, gender, and age are linked with OS ([@B3]--[@B8]). Although our study details characteristics of adult and pediatric subpopulations in a high-volume manner, work with smaller sample sizes has confirmed that prognosis in adults is poorer ([@B13]). We demonstrate that receipt of surgery is of utmost importance, whereas RT was not associated with improved outcomes in the pediatric population. It is, however, likely that there are several other pieces of information that may explain these findings. First, the lack of chemotherapy information and time to treatment are major limitations of the SEER database, and some have posited that the higher doses of chemotherapy given to children as well as earlier treatment initiation may substantially impact outcomes ([@B13]). Second, it is also likely that those patients receiving RT in any capacity may be a preselected population more likely to have poorer disease characteristics such as larger tumor size, unresectable location, and/or incomplete resection. As such, a proper comparison of both modalities remains undefined. Third, because adults were more likely to have metastatic disease and larger tumors, it is also likely that these tumors are clinically detected earlier in children than adults.

Additionally, it is compelling that the most recent subset (2004--2013) disputes many of the conclusions made in the general population of patients, indicating that perhaps modern treatment paradigms may select for RT patients in a better manner, together with improved surgical techniques and potentially even systemic therapy.

Supporting these data is institutional work from the Univer-sity of Toronto ([@B13]) analyzing 53 patients receiving VAC-IE che-motherapy. The goal of the study is to compare outcomes between pediatric (*n* = 29, defined as \<18 years) and adult (*n* = 24, ≥18 years) cohorts. Adult patients, who experienced worse OS, tended to receive lower doses of IE chemotherapy and received local therapy at a later time point than pediatric counterparts; the latter independently predicted for OS on multivariate analysis. Hence, although the authors concluded that adults have poorer OS than children, the report served to show that other factors not assessed by the majority of this and similar studies (e.g., time to local therapy) could be novel prognostic factors for survival.

Overall, prognostic factors in adults and children seem to be a difficult issue to address ([@B3], [@B6]). In adults, these included metastasis at diagnosis and pelvic primary tumor. In children, stage independently predicted survival; larger tumors and disease at axial locations were more likely to present with metastatic disease. Thus, although mirrored well by this study in context of other data, in none of these studies has causation been implied; likely, there are an interconnected set of factors that collectively lead to poor prognosis.

There are several limitations of our analysis. In addition to the inherently retrospective nature of SEER studies as well as individualized follow-up, it must be once again prominently mentioned that causation can neither be stated nor implied with these data, especially regarding treatment interventions and survival. The SEER database also does not allow for information regarding chemotherapy, surgical margins, pathological confirmation (e.g., identifying whether a few tumors were indeed low-grade Ewing sarcomas, which would be exceedingly rare), and radiation doses. In addition, the missing values for several parameters in Table [1](#T1){ref-type="table"} prevent robust conclusions even though the groups may differ based on statistical tests (likely owing to the number of unknown values). In addition, selection bias for any patient receiving surgery (or extent of surgery) can never be ruled out, as mentioned above. Moreover, confounding items such as era of treatment (especially since newer paradigms independently correlate with increased OS) are a necessary limitation that must be accepted to accumulate sufficient sample sizes. Even the inclusion of patients treated a decade ago likely encompasses a cohort with worse OS than those treated in the present decade. The diagnosis of Ewing sarcoma based on EWS/FLI translocation becoming available in the mid-1990s may also be a confounder, but to assure high volumes of patients concordant with prior studies, a facet unique to the SEER database, we opted to include all treatment eras ([@B7], [@B11], [@B12]).

Going forward, it must be recognized that there are age-based subgroups of adult and pediatric cohorts that may offer further elucidation. For instance, the majority of the adult cohort in this study was predictably skewed toward younger patients, with few who were of middle and advanced age. The role of various treatment paradigms in these subgroups is uncertain. Similarly, the infant (\<12 months) subgroup has been studied as another example, determining a potential increase in early death but similar OS ([@B14]). In addition, studying a large-volume cohort of ESFTs treated in the present decade using the most modern surgical techniques, chemotherapy regimens, and radiotherapy technologies \[including proton beam therapy ([@B15], [@B16])\] is of great necessity to determine that the results presented herein are accurate and representative of modern treatment paradigms.

Conclusion {#S5}
==========

In our high-volume comparison of pediatric vs. adult ESFT patients, adult patients had a poorer prognosis and were more likely to present with PNET histology, along with DM and soft tissue primary site. When adjusting for potential confounders on multivariate analysis, adult patients were independently associated with worse OS, along with male gender, metastatic disease, non-extremity bone location, treatment era, and PNET histology.
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